🇺🇸 FDA
Pipeline program

Columvi 10 mg concentrate for solution for infusion, Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., RoActemra 20 mg/mL concentrate for solution for infusion

NP30179

Phase 2 small_molecule active

Quick answer

Columvi 10 mg concentrate for solution for infusion, Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., RoActemra 20 mg/mL concentrate for solution for infusion for Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials